The same combination of anti-DR5 agonist IGM-8444 with birinapant is taking place for relapsed, refractory, or newly diagnosed cancers, which include soft tissue sarcoma and chondrosarcoma, in a phase 1a/1b study (ClinicalTrials.gov identifier: NCT04553692) and is still recruiting. This evidence concerns the gene TNFRSF10B and cancer.